Hinge Health's Platform Pivot: From MSK Leader to Multi-Condition Care Machine

A $105M bet on GI and a migraine program with 450 clients underscore a strategy shift that's launching HNGE into a new growth orbit — with the tape and fundamentals confirming the move.

HNGE · Earnings Call · 2026-08-04

Sizing the Quarter: The Numbers Did the Talking

Daniel Perez opened the call with a word he doesn't use casually — “outstanding” — and the Q2 print backed it up. Revenue of $213M grew 53% year-over-year, beating guidance by $11M at the midpoint. The beat was driven entirely by yield improvement, a durable, operationally-driven lever: CFO James Budge noted the upside was "all yield driven," not from lives or ASP. Operating income more than doubled to $62M, and free cash flow tripled to $100M, a 47% margin — an extraordinary figure for a company growing 50%+. “We're seeing substantial operating leverage. Our operating income more than doubled from a year ago to $62 million, and operating margin expanded to 29% from 19%.” — Daniel Perez, Co-Founder and CEO · 2026-08-04 That operating leverage is visible in the fundamentals: gross margin up 6pp in a year, and headed higher with AI-driven care-team efficiency.

The Pivot: Turning the Platform Into a Condition-Agnostic Engine

The real story is what Hinge is becoming. This quarter marks a genuine, multi-product strategic inflection — from a digital PT pure-play to a platform automating care across MSK, migraine care, and now gastrointestinal health.

We're not just talking about TAM expansion, we're proving the vision with real products, real client demand, and real member engagement.
Daniel Perez, Co-Founder and CEO · 2026-08-04

The most tangible proof: the acquisition of Cylinder Health for $105M in cash — essentially one quarter of free cash flow. Cylinder brings ~100 clients, 2M covered lives, and established PBM/health-plan partnerships, giving Hinge an 18–24 month head start. Management's messaging is disciplined — GI will contribute just $7–8M in 2026, with a broader rollout in 2027 and real scaling in 2028 after a full selling season. “We expect it to close, call it, end of August, early September... it starts to expand in 2028 after we get through a full selling season with our expanded sales force.” — James Budge, CFO · 2026-08-04 The strategic logic is compelling — GI is highly comorbid with MSK and migraine, shares the same gut-brain mechanisms, and fits the existing sales motion. But it's also a significant integration and execution commitment. Analysts pressed on this repeatedly, and management's answers were reassuring: nearly all of Cylinder's employees are expected to transition, and long-term roles have been offered to their go-to-market leadership.

The Tape and the Verdict

The market has voted emphatically. HNGE is up ~135% full-history and ~150% in the last 90 days, sitting just 3.4% below its all-time high. At ~5x TTM revenue, the valuation already prices in a great deal of the multi-product story. The risk is that the exceptional yield trends — now guided to 4.45% for 2026 — normalize as the law of large numbers sets in, and that the GI integration proves more complex than the current narrative suggests. But the fundamentals are strengthening, the cash flow funds the ambition, and the GI care expansion meaningfully enlarges the addressable market. This is a company that has earned the benefit of the doubt — and the tape is saying so.